{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T20:42:58Z","timestamp":1696624978072},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T00:00:00Z","timestamp":1398297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40261-014-0194-1","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T10:56:17Z","timestamp":1398250577000},"page":"449-456","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters"],"prefix":"10.1007","volume":"34","author":[{"given":"Rene A.","family":"Braeckman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Stirtan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paresh N.","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,24]]},"reference":[{"key":"194_CR1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","volume":"169","author":"ES Ford","year":"2009","unstructured":"Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169:572\u20138.","journal-title":"Arch Intern Med."},{"key":"194_CR2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292\u2013333.","journal-title":"Circulation."},{"key":"194_CR3","unstructured":"Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013."},{"key":"194_CR4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","volume":"108","author":"HE Bays","year":"2011","unstructured":"Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682\u201390.","journal-title":"Am J Cardiol."},{"key":"194_CR5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","volume":"110","author":"CM Ballantyne","year":"2012","unstructured":"Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984\u201392.","journal-title":"Am J Cardiol."},{"key":"194_CR6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1734-1140(10)70311-X","volume":"62","author":"C Arnold","year":"2010","unstructured":"Arnold C, Konkel A, Fischer R, et al. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep. 2010;62:536\u201347.","journal-title":"Pharmacol Rep."},{"key":"194_CR7","unstructured":"Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011."},{"key":"194_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0091270004271404","volume":"45","author":"DJ Greenblatt","year":"2005","unstructured":"Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45:127\u201332.","journal-title":"J Clin Pharmacol."},{"key":"194_CR9","doi-asserted-by":"crossref","first-page":"35C","DOI":"10.1016\/j.amjcard.2006.11.020","volume":"99","author":"HE Bays","year":"2007","unstructured":"Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C\u201343C.","journal-title":"Am J Cardiol."},{"key":"194_CR10","doi-asserted-by":"crossref","unstructured":"Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111:1652\u201362.","DOI":"10.1017\/S000711451300425X"},{"key":"194_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2125.2001.01358.x","volume":"51","author":"RA Yates","year":"2001","unstructured":"Yates RA, Wong J, Seiberling M, et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001;51:429\u201335.","journal-title":"Br J Clin Pharmacol."},{"key":"194_CR12","first-page":"890","volume":"52","author":"M Rahimy","year":"2002","unstructured":"Rahimy M, Hallen B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung. 2002;52:890\u20135.","journal-title":"Arzneimittelforschung."},{"key":"194_CR13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00228-008-0534-2","volume":"64","author":"L Almeida","year":"2008","unstructured":"Almeida L, Falcao A, Vaz-da-Silva M, et al. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol. 2008;64:961\u20136.","journal-title":"Eur J Clin Pharmacol."},{"key":"194_CR14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1592\/phco.28.7.895","volume":"28","author":"JJ Zimmerman","year":"2008","unstructured":"Zimmerman JJ, Raible DG, Harper DM, et al. Evaluation of a potential tigecycline-warfarin drug interaction. Pharmacotherapy. 2008;28:895\u2013905.","journal-title":"Pharmacotherapy."},{"key":"194_CR15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2009.03384.x","volume":"67","author":"G Walker","year":"2009","unstructured":"Walker G, Mandagere A, Dufton C, et al. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol. 2009;67:527\u201334.","journal-title":"Br J Clin Pharmacol."},{"key":"194_CR16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/0091270010378119","volume":"51","author":"R Frey","year":"2011","unstructured":"Frey R, Muck W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol. 2011;51:1051\u201360.","journal-title":"J Clin Pharmacol."},{"key":"194_CR17","unstructured":"Guidance for industry. Drug interaction studies\u2014study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services; Food and Drug Administration. http:\/\/www.fda.gov\/OHRMS\/DOCKETS\/98fr\/06d-0344-gdl0001.pdf . Accessed 25 March 2014."},{"key":"194_CR18","unstructured":"Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Devel. 2013 (Epub ahead of print). doi: 10.1002\/cpdd.84\/abstract ."},{"key":"194_CR19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0952-3278(97)90421-X","volume":"57","author":"JJ Agren","year":"1997","unstructured":"Agren JJ, Vaisanen S, Hanninen O, et al. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997;57:419\u201321.","journal-title":"Prostaglandins Leukot Essent Fatty Acids."},{"key":"194_CR20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V81.7.1871.1871","volume":"81","author":"WE Kaminski","year":"1993","unstructured":"Kaminski WE, Jendraschak E, Kiefl R, et al. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood. 1993;81:1871\u20139.","journal-title":"Blood."},{"key":"194_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0049-3848(00)00233-4","volume":"99","author":"M Thorwest","year":"2000","unstructured":"Thorwest M, Balling E, Kristensen SD, et al. Dietary fish oil reduces microvascular thrombosis in a porcine experimental model. Thromb Res. 2000;99:203\u20138.","journal-title":"Thromb Res."},{"issue":"Suppl","key":"194_CR22","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1007\/s11745-001-0689-5","volume":"36","author":"C Schacky von","year":"2001","unstructured":"von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids. 2001;36(Suppl):S99\u2013102.","journal-title":"Lipids."},{"key":"194_CR23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/01.ASN.0000032547.12173.5E","volume":"13","author":"PG Schmitz","year":"2002","unstructured":"Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002;13:184\u201390.","journal-title":"J Am Soc Nephrol."},{"key":"194_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9149(97)89130-8","volume":"77","author":"J Eritsland","year":"1996","unstructured":"Eritsland J, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996;77:31\u20136.","journal-title":"Am J Cardiol."},{"key":"194_CR25","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1345\/aph.1A314","volume":"36","author":"DN Carroll","year":"2002","unstructured":"Carroll DN, Roth MT. Evidence for the cardioprotective effects of omega-3 Fatty acids. Ann Pharmacother. 2002;36:1950\u20136.","journal-title":"Ann Pharmacother."},{"key":"194_CR26","doi-asserted-by":"crossref","first-page":"1687S","DOI":"10.1093\/ajcn\/65.5.1687S","volume":"65","author":"HR Knapp","year":"1997","unstructured":"Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65:1687S\u201398S.","journal-title":"Am J Clin Nutr."},{"key":"194_CR27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00001721-199502000-00003","volume":"6","author":"J Eritsland","year":"1995","unstructured":"Eritsland J, Arnesen H, Seljeflot I, et al. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis. 1995;6:17\u201322.","journal-title":"Blood Coagul Fibrinolysis."},{"key":"194_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1008852127668","volume":"5","author":"NK Bender","year":"1998","unstructured":"Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998;5:257\u201361.","journal-title":"J Thromb Thrombolysis."},{"key":"194_CR29","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2006.11.021","volume":"99","author":"WS Harris","year":"2007","unstructured":"Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007;99:44C\u20136C.","journal-title":"Am J Cardiol."},{"key":"194_CR30","unstructured":"Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0194-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0194-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0194-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T07:31:16Z","timestamp":1597735876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0194-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,24]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0194-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,24]]}}}